nodes	percent_of_prediction	percent_of_DWPC	metapath
Raltegravir—UGT1A1—Etoposide—testicular cancer	0.375	1	CbGbCtD
Raltegravir—CCR1—seminal vesicle—testicular cancer	0.00812	0.509	CbGeAlD
Raltegravir—CCR1—female gonad—testicular cancer	0.00477	0.299	CbGeAlD
Raltegravir—CCR1—lymph node—testicular cancer	0.00307	0.192	CbGeAlD
Raltegravir—Rash—Dactinomycin—testicular cancer	0.000477	0.000784	CcSEcCtD
Raltegravir—Decreased appetite—Etoposide—testicular cancer	0.000476	0.000782	CcSEcCtD
Raltegravir—Diarrhoea—Ifosfamide—testicular cancer	0.000474	0.000779	CcSEcCtD
Raltegravir—Renal failure—Epirubicin—testicular cancer	0.000473	0.000777	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Etoposide—testicular cancer	0.000473	0.000776	CcSEcCtD
Raltegravir—Body temperature increased—Cisplatin—testicular cancer	0.000473	0.000776	CcSEcCtD
Raltegravir—Fatigue—Etoposide—testicular cancer	0.000472	0.000775	CcSEcCtD
Raltegravir—Neuropathy peripheral—Epirubicin—testicular cancer	0.000472	0.000775	CcSEcCtD
Raltegravir—Constipation—Etoposide—testicular cancer	0.000468	0.000769	CcSEcCtD
Raltegravir—Pain—Etoposide—testicular cancer	0.000468	0.000769	CcSEcCtD
Raltegravir—Neutropenia—Doxorubicin—testicular cancer	0.000467	0.000767	CcSEcCtD
Raltegravir—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.000464	0.000762	CcSEcCtD
Raltegravir—Hepatitis—Methotrexate—testicular cancer	0.000462	0.000758	CcSEcCtD
Raltegravir—Haematuria—Epirubicin—testicular cancer	0.000459	0.000754	CcSEcCtD
Raltegravir—Dizziness—Ifosfamide—testicular cancer	0.000459	0.000753	CcSEcCtD
Raltegravir—Urinary tract disorder—Methotrexate—testicular cancer	0.000456	0.000749	CcSEcCtD
Raltegravir—Hepatobiliary disease—Epirubicin—testicular cancer	0.000455	0.000748	CcSEcCtD
Raltegravir—Weight increased—Doxorubicin—testicular cancer	0.000455	0.000747	CcSEcCtD
Raltegravir—Epistaxis—Epirubicin—testicular cancer	0.000454	0.000746	CcSEcCtD
Raltegravir—Urethral disorder—Methotrexate—testicular cancer	0.000453	0.000743	CcSEcCtD
Raltegravir—Weight decreased—Doxorubicin—testicular cancer	0.000452	0.000742	CcSEcCtD
Raltegravir—Feeling abnormal—Etoposide—testicular cancer	0.000451	0.000741	CcSEcCtD
Raltegravir—Hyperglycaemia—Doxorubicin—testicular cancer	0.000451	0.00074	CcSEcCtD
Raltegravir—Nausea—Dactinomycin—testicular cancer	0.000449	0.000738	CcSEcCtD
Raltegravir—Gastrointestinal pain—Etoposide—testicular cancer	0.000448	0.000735	CcSEcCtD
Raltegravir—Infestation—Doxorubicin—testicular cancer	0.000445	0.000731	CcSEcCtD
Raltegravir—Infestation NOS—Doxorubicin—testicular cancer	0.000445	0.000731	CcSEcCtD
Raltegravir—Visual impairment—Methotrexate—testicular cancer	0.000445	0.000731	CcSEcCtD
Raltegravir—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.000442	0.000725	CcSEcCtD
Raltegravir—Vomiting—Ifosfamide—testicular cancer	0.000441	0.000724	CcSEcCtD
Raltegravir—Hypersensitivity—Cisplatin—testicular cancer	0.00044	0.000723	CcSEcCtD
Raltegravir—Renal failure—Doxorubicin—testicular cancer	0.000438	0.000719	CcSEcCtD
Raltegravir—Rash—Ifosfamide—testicular cancer	0.000437	0.000718	CcSEcCtD
Raltegravir—Dermatitis—Ifosfamide—testicular cancer	0.000437	0.000717	CcSEcCtD
Raltegravir—Erythema multiforme—Methotrexate—testicular cancer	0.000437	0.000717	CcSEcCtD
Raltegravir—Neuropathy peripheral—Doxorubicin—testicular cancer	0.000437	0.000717	CcSEcCtD
Raltegravir—Urticaria—Etoposide—testicular cancer	0.000435	0.000714	CcSEcCtD
Raltegravir—Abdominal pain—Etoposide—testicular cancer	0.000433	0.000711	CcSEcCtD
Raltegravir—Body temperature increased—Etoposide—testicular cancer	0.000433	0.000711	CcSEcCtD
Raltegravir—Hepatitis—Epirubicin—testicular cancer	0.000432	0.00071	CcSEcCtD
Raltegravir—Eye disorder—Methotrexate—testicular cancer	0.000432	0.000709	CcSEcCtD
Raltegravir—Tinnitus—Methotrexate—testicular cancer	0.000431	0.000707	CcSEcCtD
Raltegravir—Hypoaesthesia—Epirubicin—testicular cancer	0.00043	0.000706	CcSEcCtD
Raltegravir—Asthenia—Cisplatin—testicular cancer	0.000429	0.000704	CcSEcCtD
Raltegravir—Cardiac disorder—Methotrexate—testicular cancer	0.000429	0.000704	CcSEcCtD
Raltegravir—Urinary tract disorder—Epirubicin—testicular cancer	0.000427	0.000701	CcSEcCtD
Raltegravir—Oedema peripheral—Epirubicin—testicular cancer	0.000426	0.000699	CcSEcCtD
Raltegravir—Haematuria—Doxorubicin—testicular cancer	0.000425	0.000697	CcSEcCtD
Raltegravir—Connective tissue disorder—Epirubicin—testicular cancer	0.000425	0.000697	CcSEcCtD
Raltegravir—Urethral disorder—Epirubicin—testicular cancer	0.000424	0.000696	CcSEcCtD
Raltegravir—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000421	0.000692	CcSEcCtD
Raltegravir—Epistaxis—Doxorubicin—testicular cancer	0.00042	0.00069	CcSEcCtD
Raltegravir—Angiopathy—Methotrexate—testicular cancer	0.000419	0.000688	CcSEcCtD
Raltegravir—Immune system disorder—Methotrexate—testicular cancer	0.000417	0.000685	CcSEcCtD
Raltegravir—Visual impairment—Epirubicin—testicular cancer	0.000416	0.000684	CcSEcCtD
Raltegravir—Mediastinal disorder—Methotrexate—testicular cancer	0.000416	0.000683	CcSEcCtD
Raltegravir—Chills—Methotrexate—testicular cancer	0.000414	0.00068	CcSEcCtD
Raltegravir—Nausea—Ifosfamide—testicular cancer	0.000412	0.000676	CcSEcCtD
Raltegravir—Diarrhoea—Cisplatin—testicular cancer	0.000409	0.000672	CcSEcCtD
Raltegravir—Erythema multiforme—Epirubicin—testicular cancer	0.000409	0.000671	CcSEcCtD
Raltegravir—Alopecia—Methotrexate—testicular cancer	0.000408	0.00067	CcSEcCtD
Raltegravir—Mental disorder—Methotrexate—testicular cancer	0.000405	0.000664	CcSEcCtD
Raltegravir—Eye disorder—Epirubicin—testicular cancer	0.000404	0.000663	CcSEcCtD
Raltegravir—Hypersensitivity—Etoposide—testicular cancer	0.000404	0.000663	CcSEcCtD
Raltegravir—Tinnitus—Epirubicin—testicular cancer	0.000403	0.000662	CcSEcCtD
Raltegravir—Erythema—Methotrexate—testicular cancer	0.000402	0.00066	CcSEcCtD
Raltegravir—Malnutrition—Methotrexate—testicular cancer	0.000402	0.00066	CcSEcCtD
Raltegravir—Cardiac disorder—Epirubicin—testicular cancer	0.000401	0.000659	CcSEcCtD
Raltegravir—Hepatitis—Doxorubicin—testicular cancer	0.0004	0.000657	CcSEcCtD
Raltegravir—Hypoaesthesia—Doxorubicin—testicular cancer	0.000398	0.000653	CcSEcCtD
Raltegravir—Urinary tract disorder—Doxorubicin—testicular cancer	0.000395	0.000648	CcSEcCtD
Raltegravir—Oedema peripheral—Doxorubicin—testicular cancer	0.000394	0.000647	CcSEcCtD
Raltegravir—Dysgeusia—Methotrexate—testicular cancer	0.000394	0.000646	CcSEcCtD
Raltegravir—Asthenia—Etoposide—testicular cancer	0.000393	0.000645	CcSEcCtD
Raltegravir—Connective tissue disorder—Doxorubicin—testicular cancer	0.000393	0.000645	CcSEcCtD
Raltegravir—Angiopathy—Epirubicin—testicular cancer	0.000392	0.000644	CcSEcCtD
Raltegravir—Urethral disorder—Doxorubicin—testicular cancer	0.000392	0.000644	CcSEcCtD
Raltegravir—Immune system disorder—Epirubicin—testicular cancer	0.00039	0.000641	CcSEcCtD
Raltegravir—Mediastinal disorder—Epirubicin—testicular cancer	0.000389	0.00064	CcSEcCtD
Raltegravir—Back pain—Methotrexate—testicular cancer	0.000389	0.000638	CcSEcCtD
Raltegravir—Chills—Epirubicin—testicular cancer	0.000388	0.000637	CcSEcCtD
Raltegravir—Pruritus—Etoposide—testicular cancer	0.000387	0.000636	CcSEcCtD
Raltegravir—Visual impairment—Doxorubicin—testicular cancer	0.000385	0.000633	CcSEcCtD
Raltegravir—Alopecia—Epirubicin—testicular cancer	0.000382	0.000627	CcSEcCtD
Raltegravir—Vomiting—Cisplatin—testicular cancer	0.00038	0.000624	CcSEcCtD
Raltegravir—Mental disorder—Epirubicin—testicular cancer	0.000379	0.000622	CcSEcCtD
Raltegravir—Erythema multiforme—Doxorubicin—testicular cancer	0.000378	0.000621	CcSEcCtD
Raltegravir—Rash—Cisplatin—testicular cancer	0.000377	0.000619	CcSEcCtD
Raltegravir—Dermatitis—Cisplatin—testicular cancer	0.000377	0.000618	CcSEcCtD
Raltegravir—Erythema—Epirubicin—testicular cancer	0.000376	0.000618	CcSEcCtD
Raltegravir—Malnutrition—Epirubicin—testicular cancer	0.000376	0.000618	CcSEcCtD
Raltegravir—Diarrhoea—Etoposide—testicular cancer	0.000375	0.000615	CcSEcCtD
Raltegravir—Eye disorder—Doxorubicin—testicular cancer	0.000374	0.000614	CcSEcCtD
Raltegravir—Ill-defined disorder—Methotrexate—testicular cancer	0.000373	0.000612	CcSEcCtD
Raltegravir—Tinnitus—Doxorubicin—testicular cancer	0.000373	0.000612	CcSEcCtD
Raltegravir—Anaemia—Methotrexate—testicular cancer	0.000372	0.00061	CcSEcCtD
Raltegravir—Cardiac disorder—Doxorubicin—testicular cancer	0.000371	0.000609	CcSEcCtD
Raltegravir—Flatulence—Epirubicin—testicular cancer	0.000371	0.000609	CcSEcCtD
Raltegravir—Dysgeusia—Epirubicin—testicular cancer	0.000368	0.000605	CcSEcCtD
Raltegravir—Nervousness—Epirubicin—testicular cancer	0.000365	0.0006	CcSEcCtD
Raltegravir—Back pain—Epirubicin—testicular cancer	0.000364	0.000598	CcSEcCtD
Raltegravir—Angiopathy—Doxorubicin—testicular cancer	0.000363	0.000596	CcSEcCtD
Raltegravir—Malaise—Methotrexate—testicular cancer	0.000362	0.000595	CcSEcCtD
Raltegravir—Dizziness—Etoposide—testicular cancer	0.000362	0.000595	CcSEcCtD
Raltegravir—Immune system disorder—Doxorubicin—testicular cancer	0.000361	0.000593	CcSEcCtD
Raltegravir—Vertigo—Methotrexate—testicular cancer	0.000361	0.000593	CcSEcCtD
Raltegravir—Mediastinal disorder—Doxorubicin—testicular cancer	0.00036	0.000592	CcSEcCtD
Raltegravir—Chills—Doxorubicin—testicular cancer	0.000359	0.000589	CcSEcCtD
Raltegravir—Nausea—Cisplatin—testicular cancer	0.000355	0.000583	CcSEcCtD
Raltegravir—Alopecia—Doxorubicin—testicular cancer	0.000353	0.00058	CcSEcCtD
Raltegravir—Cough—Methotrexate—testicular cancer	0.000351	0.000576	CcSEcCtD
Raltegravir—Mental disorder—Doxorubicin—testicular cancer	0.00035	0.000575	CcSEcCtD
Raltegravir—Ill-defined disorder—Epirubicin—testicular cancer	0.000349	0.000573	CcSEcCtD
Raltegravir—Vomiting—Etoposide—testicular cancer	0.000348	0.000572	CcSEcCtD
Raltegravir—Malnutrition—Doxorubicin—testicular cancer	0.000348	0.000572	CcSEcCtD
Raltegravir—Erythema—Doxorubicin—testicular cancer	0.000348	0.000572	CcSEcCtD
Raltegravir—Anaemia—Epirubicin—testicular cancer	0.000348	0.000571	CcSEcCtD
Raltegravir—Agitation—Epirubicin—testicular cancer	0.000346	0.000568	CcSEcCtD
Raltegravir—Rash—Etoposide—testicular cancer	0.000345	0.000567	CcSEcCtD
Raltegravir—Dermatitis—Etoposide—testicular cancer	0.000345	0.000567	CcSEcCtD
Raltegravir—Headache—Etoposide—testicular cancer	0.000343	0.000563	CcSEcCtD
Raltegravir—Flatulence—Doxorubicin—testicular cancer	0.000343	0.000563	CcSEcCtD
Raltegravir—Myalgia—Methotrexate—testicular cancer	0.000342	0.000562	CcSEcCtD
Raltegravir—Arthralgia—Methotrexate—testicular cancer	0.000342	0.000562	CcSEcCtD
Raltegravir—Chest pain—Methotrexate—testicular cancer	0.000342	0.000562	CcSEcCtD
Raltegravir—Dysgeusia—Doxorubicin—testicular cancer	0.000341	0.00056	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.00034	0.000558	CcSEcCtD
Raltegravir—Malaise—Epirubicin—testicular cancer	0.000339	0.000557	CcSEcCtD
Raltegravir—Discomfort—Methotrexate—testicular cancer	0.000338	0.000555	CcSEcCtD
Raltegravir—Nervousness—Doxorubicin—testicular cancer	0.000338	0.000555	CcSEcCtD
Raltegravir—Vertigo—Epirubicin—testicular cancer	0.000338	0.000555	CcSEcCtD
Raltegravir—Back pain—Doxorubicin—testicular cancer	0.000337	0.000553	CcSEcCtD
Raltegravir—Palpitations—Epirubicin—testicular cancer	0.000332	0.000546	CcSEcCtD
Raltegravir—Confusional state—Methotrexate—testicular cancer	0.000331	0.000543	CcSEcCtD
Raltegravir—Cough—Epirubicin—testicular cancer	0.000328	0.000539	CcSEcCtD
Raltegravir—Infection—Methotrexate—testicular cancer	0.000326	0.000535	CcSEcCtD
Raltegravir—Nausea—Etoposide—testicular cancer	0.000325	0.000534	CcSEcCtD
Raltegravir—Hypertension—Epirubicin—testicular cancer	0.000325	0.000533	CcSEcCtD
Raltegravir—Ill-defined disorder—Doxorubicin—testicular cancer	0.000323	0.00053	CcSEcCtD
Raltegravir—Nervous system disorder—Methotrexate—testicular cancer	0.000322	0.000528	CcSEcCtD
Raltegravir—Anaemia—Doxorubicin—testicular cancer	0.000322	0.000528	CcSEcCtD
Raltegravir—Thrombocytopenia—Methotrexate—testicular cancer	0.000321	0.000527	CcSEcCtD
Raltegravir—Arthralgia—Epirubicin—testicular cancer	0.00032	0.000526	CcSEcCtD
Raltegravir—Chest pain—Epirubicin—testicular cancer	0.00032	0.000526	CcSEcCtD
Raltegravir—Myalgia—Epirubicin—testicular cancer	0.00032	0.000526	CcSEcCtD
Raltegravir—Agitation—Doxorubicin—testicular cancer	0.00032	0.000525	CcSEcCtD
Raltegravir—Anxiety—Epirubicin—testicular cancer	0.000319	0.000524	CcSEcCtD
Raltegravir—Skin disorder—Methotrexate—testicular cancer	0.000319	0.000523	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000318	0.000522	CcSEcCtD
Raltegravir—Hyperhidrosis—Methotrexate—testicular cancer	0.000317	0.000521	CcSEcCtD
Raltegravir—Discomfort—Epirubicin—testicular cancer	0.000316	0.00052	CcSEcCtD
Raltegravir—Malaise—Doxorubicin—testicular cancer	0.000314	0.000515	CcSEcCtD
Raltegravir—Dry mouth—Epirubicin—testicular cancer	0.000313	0.000514	CcSEcCtD
Raltegravir—Vertigo—Doxorubicin—testicular cancer	0.000313	0.000514	CcSEcCtD
Raltegravir—Confusional state—Epirubicin—testicular cancer	0.00031	0.000508	CcSEcCtD
Raltegravir—Palpitations—Doxorubicin—testicular cancer	0.000308	0.000505	CcSEcCtD
Raltegravir—Infection—Epirubicin—testicular cancer	0.000305	0.000501	CcSEcCtD
Raltegravir—Cough—Doxorubicin—testicular cancer	0.000304	0.000499	CcSEcCtD
Raltegravir—Nervous system disorder—Epirubicin—testicular cancer	0.000301	0.000494	CcSEcCtD
Raltegravir—Thrombocytopenia—Epirubicin—testicular cancer	0.000301	0.000494	CcSEcCtD
Raltegravir—Hypertension—Doxorubicin—testicular cancer	0.000301	0.000493	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000299	0.000491	CcSEcCtD
Raltegravir—Skin disorder—Epirubicin—testicular cancer	0.000298	0.00049	CcSEcCtD
Raltegravir—Hyperhidrosis—Epirubicin—testicular cancer	0.000297	0.000487	CcSEcCtD
Raltegravir—Insomnia—Methotrexate—testicular cancer	0.000297	0.000487	CcSEcCtD
Raltegravir—Chest pain—Doxorubicin—testicular cancer	0.000296	0.000487	CcSEcCtD
Raltegravir—Myalgia—Doxorubicin—testicular cancer	0.000296	0.000487	CcSEcCtD
Raltegravir—Arthralgia—Doxorubicin—testicular cancer	0.000296	0.000487	CcSEcCtD
Raltegravir—Anxiety—Doxorubicin—testicular cancer	0.000295	0.000485	CcSEcCtD
Raltegravir—Paraesthesia—Methotrexate—testicular cancer	0.000295	0.000484	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000294	0.000483	CcSEcCtD
Raltegravir—Discomfort—Doxorubicin—testicular cancer	0.000293	0.000481	CcSEcCtD
Raltegravir—Somnolence—Methotrexate—testicular cancer	0.000292	0.000479	CcSEcCtD
Raltegravir—Dry mouth—Doxorubicin—testicular cancer	0.00029	0.000476	CcSEcCtD
Raltegravir—Dyspepsia—Methotrexate—testicular cancer	0.000289	0.000474	CcSEcCtD
Raltegravir—Confusional state—Doxorubicin—testicular cancer	0.000286	0.00047	CcSEcCtD
Raltegravir—Decreased appetite—Methotrexate—testicular cancer	0.000285	0.000468	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000283	0.000465	CcSEcCtD
Raltegravir—Fatigue—Methotrexate—testicular cancer	0.000283	0.000464	CcSEcCtD
Raltegravir—Infection—Doxorubicin—testicular cancer	0.000282	0.000463	CcSEcCtD
Raltegravir—Pain—Methotrexate—testicular cancer	0.000281	0.000461	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.00028	0.000459	CcSEcCtD
Raltegravir—Nervous system disorder—Doxorubicin—testicular cancer	0.000279	0.000457	CcSEcCtD
Raltegravir—Thrombocytopenia—Doxorubicin—testicular cancer	0.000278	0.000457	CcSEcCtD
Raltegravir—Insomnia—Epirubicin—testicular cancer	0.000278	0.000456	CcSEcCtD
Raltegravir—Skin disorder—Doxorubicin—testicular cancer	0.000276	0.000453	CcSEcCtD
Raltegravir—Paraesthesia—Epirubicin—testicular cancer	0.000276	0.000453	CcSEcCtD
Raltegravir—Hyperhidrosis—Doxorubicin—testicular cancer	0.000275	0.000451	CcSEcCtD
Raltegravir—Somnolence—Epirubicin—testicular cancer	0.000273	0.000448	CcSEcCtD
Raltegravir—Feeling abnormal—Methotrexate—testicular cancer	0.00027	0.000444	CcSEcCtD
Raltegravir—Dyspepsia—Epirubicin—testicular cancer	0.00027	0.000444	CcSEcCtD
Raltegravir—Gastrointestinal pain—Methotrexate—testicular cancer	0.000268	0.000441	CcSEcCtD
Raltegravir—Decreased appetite—Epirubicin—testicular cancer	0.000267	0.000438	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000265	0.000435	CcSEcCtD
Raltegravir—Fatigue—Epirubicin—testicular cancer	0.000265	0.000435	CcSEcCtD
Raltegravir—Pain—Epirubicin—testicular cancer	0.000263	0.000431	CcSEcCtD
Raltegravir—Constipation—Epirubicin—testicular cancer	0.000263	0.000431	CcSEcCtD
Raltegravir—Urticaria—Methotrexate—testicular cancer	0.000261	0.000428	CcSEcCtD
Raltegravir—Abdominal pain—Methotrexate—testicular cancer	0.000259	0.000426	CcSEcCtD
Raltegravir—Body temperature increased—Methotrexate—testicular cancer	0.000259	0.000426	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000259	0.000425	CcSEcCtD
Raltegravir—Insomnia—Doxorubicin—testicular cancer	0.000257	0.000422	CcSEcCtD
Raltegravir—Paraesthesia—Doxorubicin—testicular cancer	0.000255	0.000419	CcSEcCtD
Raltegravir—Feeling abnormal—Epirubicin—testicular cancer	0.000253	0.000415	CcSEcCtD
Raltegravir—Somnolence—Doxorubicin—testicular cancer	0.000253	0.000415	CcSEcCtD
Raltegravir—Gastrointestinal pain—Epirubicin—testicular cancer	0.000251	0.000412	CcSEcCtD
Raltegravir—Dyspepsia—Doxorubicin—testicular cancer	0.00025	0.000411	CcSEcCtD
Raltegravir—Decreased appetite—Doxorubicin—testicular cancer	0.000247	0.000405	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000245	0.000403	CcSEcCtD
Raltegravir—Fatigue—Doxorubicin—testicular cancer	0.000245	0.000402	CcSEcCtD
Raltegravir—Urticaria—Epirubicin—testicular cancer	0.000244	0.0004	CcSEcCtD
Raltegravir—Pain—Doxorubicin—testicular cancer	0.000243	0.000399	CcSEcCtD
Raltegravir—Constipation—Doxorubicin—testicular cancer	0.000243	0.000399	CcSEcCtD
Raltegravir—Abdominal pain—Epirubicin—testicular cancer	0.000243	0.000399	CcSEcCtD
Raltegravir—Body temperature increased—Epirubicin—testicular cancer	0.000243	0.000399	CcSEcCtD
Raltegravir—Hypersensitivity—Methotrexate—testicular cancer	0.000242	0.000397	CcSEcCtD
Raltegravir—Asthenia—Methotrexate—testicular cancer	0.000235	0.000387	CcSEcCtD
Raltegravir—Feeling abnormal—Doxorubicin—testicular cancer	0.000234	0.000384	CcSEcCtD
Raltegravir—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000232	0.000381	CcSEcCtD
Raltegravir—Pruritus—Methotrexate—testicular cancer	0.000232	0.000381	CcSEcCtD
Raltegravir—Hypersensitivity—Epirubicin—testicular cancer	0.000226	0.000371	CcSEcCtD
Raltegravir—Urticaria—Doxorubicin—testicular cancer	0.000226	0.000371	CcSEcCtD
Raltegravir—Body temperature increased—Doxorubicin—testicular cancer	0.000225	0.000369	CcSEcCtD
Raltegravir—Abdominal pain—Doxorubicin—testicular cancer	0.000225	0.000369	CcSEcCtD
Raltegravir—Diarrhoea—Methotrexate—testicular cancer	0.000224	0.000369	CcSEcCtD
Raltegravir—Asthenia—Epirubicin—testicular cancer	0.00022	0.000362	CcSEcCtD
Raltegravir—Pruritus—Epirubicin—testicular cancer	0.000217	0.000357	CcSEcCtD
Raltegravir—Dizziness—Methotrexate—testicular cancer	0.000217	0.000356	CcSEcCtD
Raltegravir—Diarrhoea—Epirubicin—testicular cancer	0.00021	0.000345	CcSEcCtD
Raltegravir—Hypersensitivity—Doxorubicin—testicular cancer	0.000209	0.000344	CcSEcCtD
Raltegravir—Vomiting—Methotrexate—testicular cancer	0.000209	0.000343	CcSEcCtD
Raltegravir—Rash—Methotrexate—testicular cancer	0.000207	0.00034	CcSEcCtD
Raltegravir—Dermatitis—Methotrexate—testicular cancer	0.000207	0.000339	CcSEcCtD
Raltegravir—Headache—Methotrexate—testicular cancer	0.000206	0.000337	CcSEcCtD
Raltegravir—Asthenia—Doxorubicin—testicular cancer	0.000204	0.000335	CcSEcCtD
Raltegravir—Dizziness—Epirubicin—testicular cancer	0.000203	0.000333	CcSEcCtD
Raltegravir—Pruritus—Doxorubicin—testicular cancer	0.000201	0.00033	CcSEcCtD
Raltegravir—Vomiting—Epirubicin—testicular cancer	0.000195	0.000321	CcSEcCtD
Raltegravir—Nausea—Methotrexate—testicular cancer	0.000195	0.00032	CcSEcCtD
Raltegravir—Diarrhoea—Doxorubicin—testicular cancer	0.000194	0.000319	CcSEcCtD
Raltegravir—Rash—Epirubicin—testicular cancer	0.000194	0.000318	CcSEcCtD
Raltegravir—Dermatitis—Epirubicin—testicular cancer	0.000193	0.000318	CcSEcCtD
Raltegravir—Headache—Epirubicin—testicular cancer	0.000192	0.000316	CcSEcCtD
Raltegravir—Dizziness—Doxorubicin—testicular cancer	0.000188	0.000308	CcSEcCtD
Raltegravir—Nausea—Epirubicin—testicular cancer	0.000182	0.000299	CcSEcCtD
Raltegravir—Vomiting—Doxorubicin—testicular cancer	0.000181	0.000297	CcSEcCtD
Raltegravir—Rash—Doxorubicin—testicular cancer	0.000179	0.000294	CcSEcCtD
Raltegravir—Dermatitis—Doxorubicin—testicular cancer	0.000179	0.000294	CcSEcCtD
Raltegravir—Headache—Doxorubicin—testicular cancer	0.000178	0.000292	CcSEcCtD
Raltegravir—Nausea—Doxorubicin—testicular cancer	0.000169	0.000277	CcSEcCtD
